Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
公司代碼PRPO
公司名稱Precipio Inc
上市日期Jul 18, 2000
CEODanieli (Ilan S)
員工數量54
證券類型Ordinary Share
年結日Jul 18
公司地址4 Science Park
城市NEW HAVEN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編06511
電話12037877888
網址https://www.precipiodx.com/
公司代碼PRPO
上市日期Jul 18, 2000
CEODanieli (Ilan S)